AbbVie executives are sticking to their pledge to restrict annual price increases on Humira® below 10%, but even payer price protections won’t mitigate the increasing expenditures before adalimumab biosimilars hit the market. In 2023, when adalimumab biosimilars become available, the savings biosimilars represent may not be real savings at all. Pharmaceutical companies generally seek to … Continue reading What Will Cost Savings on 2023 Adalimumab Biosimilars Really Be Worth? →